Lesson
Build the Class From Ribosome to Translation Failure
Linezolid and tedizolid are oxazolidinones that bind the bacterial 50S ribosomal subunit and inhibit protein synthesis. Linezolid prevents formation of a functional 70S initiation complex, while tedizolid phosphate must first be converted by phosphatases to active tedizolid.
- Oxazolidinone scaffold
- 23S rRNA
- 50S subunit
- 70S initiation complex
- Tedizolid prodrug
Phosphatases expose the active tedizolid moiety.
Oxazolidinones occupy the bacterial ribosomal target.
Linezolid prevents formation of a productive initiation complex.
Growth stops while host and source factors determine outcome.
The target is the beginning of translation
Linezolid binds 23S rRNA in the 50S subunit and prevents productive 70S initiation-complex formation. This is distinct from cell-wall synthesis inhibition, DNA gyrase inhibition, and direct membrane disruption.
Tedizolid phosphate is not the final active form
Phosphatases convert the phosphate prodrug after oral or intravenous administration. Active tedizolid then binds the 50S subunit and suppresses bacterial protein synthesis.
Activity is usually bacteriostatic
Both labels describe bacteriostatic activity against enterococci, staphylococci, and streptococci. Clinical success still depends on site, host defenses, source control, and exposure.
The same target creates shared resistance risk
Mutations in 23S rRNA or ribosomal proteins can reduce susceptibility. A drug from the same class should not be assumed to rescue target-site resistance without current testing.
Quick check
Lesson
Read Gram-Positive Activity Without Inventing Coverage
The class is used for susceptible gram-positive organisms. Linezolid has labeled roles for selected MRSA infections and VRE E. faecium, but it has no clinical role against gram-negative pathogens. Tedizolid's current indication is narrower.
- MRSA
- VRE E. faecium
- Streptococci
- No gram-negative coverage
- 23S resistance
Use current susceptibility and a supported syndrome.
Do not transfer this indication to tedizolid.
Mixed syndromes need complete companion coverage.
Recheck source, MIC, exposure, and target-site resistance.
Linezolid has broad gram-positive utility
Current labeling includes selected pneumonia and skin infections caused by susceptible gram-positive organisms and VRE E. faecium infection including concurrent bacteremia. Species and syndrome must remain explicit.
Tedizolid is not a duplicate label
Current SIVEXTRO labeling supports ABSSSI caused by designated susceptible gram-positive organisms. Do not transfer linezolid's pneumonia or VRE indications to tedizolid.
Gram-negative pathogens require another active plan
The linezolid label states that specific gram-negative therapy is required when a gram-negative pathogen is suspected or documented. A mixed infection cannot be made complete by optimism.
Failure should trigger a resistance and source review
Repeat cultures, susceptibility, source control, adherence, route, absorption, and bacterial burden before escalating or swapping within the class.
Quick check
Lesson
Let the Syndrome Choose the Agent
Linezolid and tedizolid share a class but not a complete indication set. The selection should start with infection compartment, organism, severity, duration, oral feasibility, source control, and toxicity risk.
- Pneumonia
- Skin infection
- VRE infection
- ABSSSI
- Evidence boundary
Pneumonia, skin, and VRE roles remain syndrome specific.
Current labeling supports a six-day ABSSSI course.
Drainage and device decisions remain central.
Separate labeled use from specialist off-label reasoning.
Linezolid indications are site specific
Adult and adolescent serious indications commonly use 600 mg orally or intravenously every 12 hours. Duration differs by syndrome, and controlled-trial safety and efficacy beyond 28 days have not been evaluated.
Tedizolid is a six-day ABSSSI drug in current labeling
Adults receive 200 mg once daily for six days. A shorter labeled course does not justify expanding the syndrome or duration without a documented off-label rationale.
The catheter-related infection signal teaches spectrum discipline
A mortality imbalance appeared in seriously ill catheter-related infections, driven by patients with gram-negative, mixed, or no identified pathogens. It reinforces the danger of incomplete empiric coverage.
Source control is still pharmacology
Drainage, debridement, catheter removal, repeat blood cultures, respiratory evaluation, and infection-depth assessment can matter more than class switching.
Quick check
Lesson
Use Bioavailability to Remove Unnecessary IV Therapy
Linezolid is approximately 100 percent orally bioavailable, and tedizolid is approximately 91 percent orally bioavailable. Neither requires a route-based dose change, but organ function and toxicity still influence monitoring.
- Oral step-down
- Linezolid renal context
- Hemodialysis timing
- Tedizolid organ function
- Food
About 100 percent oral bioavailability preserves the dose.
The parent dose is unchanged, but timing and toxicity matter.
About 91 percent oral bioavailability preserves 200 mg daily.
Renal, dialysis, and hepatic impairment need no adjustment.
Linezolid makes a true one-to-one route switch
Maximum concentrations follow oral dosing rapidly and total exposure is comparable to intravenous dosing. Switch 600 mg IV every 12 hours to 600 mg orally every 12 hours when the patient can absorb and adhere.
No adjustment does not mean no renal concern
The parent linezolid exposure is similar across renal function, but metabolites accumulate. Severe renal impairment is associated with more thrombocytopenia, and about 30 percent of a dose can be removed during hemodialysis, so give after dialysis.
Tedizolid also supports route conversion
The current label reports about 91 percent oral bioavailability and no dose change between intravenous and oral routes. Food does not alter total exposure enough to require adjustment.
Tedizolid organ impairment does not change the dose
No adjustment is necessary for renal impairment, hemodialysis, or hepatic impairment. Hemodialysis does not meaningfully remove tedizolid.
Quick check
Lesson
Make Pediatric Tedizolid a Weight-Band Calculation
Current SIVEXTRO labeling extends intravenous therapy to pediatric patients at least 26 weeks gestational age and at least 1 kg. Tablets are limited to patients weighing at least 35 kg.
- Gestational age
- Weight band
- Twice-daily IV dosing
- Tablet threshold
- 50 mg per mL
These are the minimum labeled IV eligibility thresholds.
Use twice-daily IV weight bands, not the tablet.
The vial becomes 50 mg per mL.
Use NS or D5W and avoid vigorous shaking.
Route eligibility begins before tablet eligibility
A child below 35 kg can receive labeled intravenous therapy but not the tablet. Patients at least 35 kg receive 200 mg once daily orally or intravenously.
Smaller patients use twice-daily dosing
The current table uses 3 mg/kg twice daily from 1 to less than 2 kg, then fixed twice-daily dose bands from 2 to less than 35 kg. Do not force the adult frequency onto a smaller child.
The vial becomes 50 mg per mL
Reconstitute the 200 mg vial with 4 mL sterile water. Gently swirl, do not shake, inspect the solution, and then perform the labeled final dilution.
Diluent and time are operational controls
The current label permits normal saline or D5W and a one-hour infusion. The total time from reconstitution through the end of administration must not exceed 24 hours at room or refrigerated temperature.
Quick check
Lesson
Treat Every CBC as a Decision Point
Linezolid can cause anemia, leukopenia, pancytopenia, and thrombocytopenia. Tedizolid is not free of hematologic risk, particularly when exposure extends beyond its six-day labeled course.
- Weekly CBC
- Platelet trend
- Renal risk
- Duration
- Alternative therapy
Know what changed before blaming the antibiotic.
Increase frequency when duration or host risk rises.
Review causes, necessity, bleeding, and alternatives.
Do not claim prolonged marrow safety from short trials.
Weekly is the linezolid minimum
Monitor complete blood counts weekly, especially beyond two weeks and in pre-existing myelosuppression, marrow-suppressive therapy, chronic infection, severe renal impairment, or moderate to severe hepatic impairment.
Trend beats one isolated value
Compare baseline, rate of decline, affected cell lines, bleeding, infection, organ function, and competing causes. Consider discontinuation when worsening myelosuppression is attributed to linezolid.
Tedizolid's short course limits inference
Six-day trials found similar clinically significant hematologic changes between groups, but 21-day exposure showed possible duration effects and postmarketing thrombocytopenia exists.
Never promise that one agent is marrow safe
Selection should balance the labeled syndrome and duration, baseline counts, host risk, drug interactions, prior toxicity, and the feasibility of follow-up.
Quick check
Lesson
Recognize Toxicity Before It Becomes Irreversible
Prolonged linezolid exposure can injure optic and peripheral nerves. Recurrent nausea, vomiting, unexplained acidosis, or low bicarbonate can signal lactic acidosis and requires immediate evaluation.
- Optic neuropathy
- Peripheral neuropathy
- Lactic acidosis
- Visual monitoring
- Exposure duration
Promptly evaluate any new visual change.
Map the pattern and competing neurotoxins.
Repeated vomiting or acidosis needs urgent evaluation.
Twenty-eight days is not a guarantee of safety.
Visual symptoms are urgent
Prompt ophthalmic evaluation is needed for change in acuity, color vision, visual field, or clarity. Monitor visual function during treatment beyond three months and in any patient with new symptoms.
Peripheral nerve injury can persist
Ask about numbness, burning pain, paresthesia, distal weakness, balance, and competing neurotoxins. Do not assume a familiar comorbidity explains a new treatment-emergent pattern.
Lactic acidosis may announce itself through the stomach
Repeated nausea or vomiting, unexplained acidosis, or low bicarbonate should trigger immediate evaluation of lactate, pH, perfusion, infection, organ function, and medicine exposure.
Twenty-eight days is an evidence boundary
Neuropathy is reported primarily beyond 28 days, but visual effects and lactic acidosis can occur sooner. Monitoring should follow symptoms and risk, not a calendar alone.
Quick check
Lesson
Use the 2026 Interaction Language
Both current labels warn about serotonin syndrome with serotonergic agents. Linezolid also reversibly inhibits monoamine oxidase and can enhance pressor responses to tyramine, decongestants, vasopressors, and dopaminergic agents.
- Serotonin syndrome
- MAO inhibition
- Tyramine
- Pseudoephedrine
- Vasoactive titration
The 2026 labels warn about serotonin syndrome.
Neuromuscular findings sharpen the diagnosis.
Linezolid can enhance pressor responses.
Blood pressure monitoring turns risk into a plan.
Linezolid no longer fits a one-sentence blanket rule
The June 2026 label directs monitoring when serotonergic agents are used together. If serotonin syndrome occurs, consider discontinuing linezolid and or serotonergic agents as clinically appropriate and start supportive treatment.
Tedizolid also carries a current warning
The February 2026 label cites spontaneous and postmarketing reports with serotonergic coadministration. Older materials that imply no clinically relevant risk are no longer sufficient.
Recognize the syndrome
Hyperthermia, diaphoresis, agitation, clonus, hyperreflexia, tremor, rigidity, and autonomic instability require rapid assessment. Do not reduce the evaluation to mental status alone.
Linezolid can raise blood pressure through indirect interactions
Avoid large amounts of high-tyramine food. Reduce initial vasoactive doses when appropriate, titrate to effect, and monitor patients using sympathomimetics including pseudoephedrine.
Quick check
Lesson
Keep the Rest of the Safety Map Visible
Linezolid safety includes hypoglycemia, hyponatremia or SIADH, convulsions, rhabdomyolysis, C. difficile diarrhea, and blood-pressure interactions. Tedizolid requires special caution in neutropenia and also carries C. difficile and serotonergic warnings.
- Hypoglycemia
- Hyponatremia
- Rhabdomyolysis
- Neutropenia
- C. difficile
Linezolid can amplify hypoglycemia risk.
Confusion or weakness can reflect SIADH.
Rhabdomyolysis requires prompt action.
Consider an alternative when ANC is below 1,000.
Glucose can fall
Symptomatic hypoglycemia has been reported in patients receiving linezolid with insulin or oral glucose-lowering therapy. Increase glucose awareness and adjust treatment clinically if hypoglycemia occurs.
Sodium and muscle injury require targeted tests
Confusion, somnolence, weakness, or respiratory decline can reflect hyponatremia or SIADH. Muscle pain, weakness, dark urine, or elevated CPK can signal rhabdomyolysis.
Tedizolid is not well established in neutropenia
Safety and efficacy have not been adequately evaluated below an absolute neutrophil count of 1,000 cells per cubic millimeter, and animal activity fell without granulocytes. Consider an alternative.
Diarrhea can outlast the antibiotic
Both labels warn about C. difficile associated diarrhea, which can appear during therapy or more than two months later. Evaluate severity, exposure, and competing causes.
Quick check
Lesson
Close the Loop Before the First Dose
A safe oxazolidinone plan joins diagnosis, organism, site, indication, route, duration, missing spectrum, source control, interactions, laboratories, symptom surveillance, response, and a written endpoint.
- Diagnosis
- Agent choice
- Exposure
- Monitoring
- Exit criteria
Confirm a supported gram-positive use.
Keep linezolid and tedizolid plans distinct.
Cultures and toxicity share one timeline.
Write the decision thresholds before risk accumulates.
Start with a supported use
Name the syndrome, organism, susceptibility, site, severity, source, and why linezolid or tedizolid is preferred. State labeled or off-label status and the missing-spectrum plan.
Make administration reconstructable
Record dose, route, interval, start and stop dates, dialysis timing when relevant, pediatric weight band, vial concentration, final volume, infusion time, and missed-dose instructions.
Monitor the whole toxicity profile
Follow CBC, renal and hepatic trajectory, vision, neuropathy, acid-base symptoms, glucose, sodium, muscle injury, bowel pattern, blood pressure, serotonergic symptoms, and adherence.
Write the exit before risk accumulates
State when to narrow, switch to oral therapy, change agents, stop for toxicity, repeat cultures, remove a source, seek specialty input, or complete therapy.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 136 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.